A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease

Imagem de Miniatura
Arquivos
art_SALGADO_A_12_Month_Phase_3_Study_of_Pasireotide_2012.PDF (1 MB)
Citações na Scopus
517
Tipo de produção
article
Data de publicação
2012
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
MASSACHUSETTS MEDICAL SOC
Autores
COLAO, Annamaria
PETERSENN, Stephan
NEWELL-PRICE, John
FINDLING, James W.
GU, Feng
MALDONADO, Mario
SCHOENHERR, Ulrike
MILLS, David
BILLER, Beverly M. K.
Citação
NEW ENGLAND JOURNAL OF MEDICINE, v.366, n.10, p.914-924, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
BACKGROUND Cushing's disease is associated with high morbidity and mortality. Pasireotide, a potential therapy, has a unique, broad somatostatin-receptor-binding profile, with high binding affinity for somatostatin-receptor subtype 5. METHODS In this double-blind, phase 3 study, we randomly assigned 162 adults with Cushing's disease and a urinary free cortisol level of at least 1.5 times the upper limit of the normal range to receive subcutaneous pasireotide at a dose of 600 mu g (82 patients) or 900 mu g (80 patients) twice daily. Patients with urinary free cortisol not exceeding 2 times the upper limit of the normal range and not exceeding the baseline level at month 3 continued to receive their randomly assigned dose; all others received an additional 300 mu g twice daily. The primary end point was a urinary free cortisol level at or below the upper limit of the normal range at month 6 without an increased dose. Open-label treatment continued through month 12. RESULTS Twelve of the 82 patients in the 600-mu g group and 21 of the 80 patients in the 900-mu g group met the primary end point. The median urinary free cortisol level decreased by approximately 50% by month 2 and remained stable in both groups. A normal urinary free cortisol level was achieved more frequently in patients with baseline levels not exceeding 5 times the upper limit of the normal range than in patients with higher baseline levels. Serum and salivary cortisol and plasma corticotropin levels decreased, and clinical signs and symptoms of Cushing's disease diminished. Pasireotide was associated with hyperglycemia-related adverse events in 118 of 162 patients; other adverse events were similar to those associated with other somatostatin analogues. Despite declines in cortisol levels, blood glucose and glycated hemoglobin levels increased soon after treatment initiation and then stabilized; treatment with a glucose- lowering medication was initiated in 74 of 162 patients. CONCLUSIONS The significant decrease in cortisol levels in patients with Cushing's disease who received pasireotide supports its potential use as a targeted treatment for corticotropinsecreting pituitary adenomas. (Funded by Novartis Pharma; ClinicalTrials.gov number, NCT00434148.)
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/1341
Referências
  1. Arnaldi G, 2003, J CLIN ENDOCR METAB, V88, P5593, DOI 10.1210/jc.2003-030871
  2. Batista DL, 2006, J CLIN ENDOCR METAB, V91, P4482, DOI 10.1210/jc.2006-1245
  3. Biller BMK, 2008, J CLIN ENDOCR METAB, V93, P2454, DOI 10.1210/jc.2007-2734
  4. Boscaro M, 2009, J CLIN ENDOCR METAB, V94, P115, DOI 10.1210/jc.2008-1008
  5. Bruns C, 2002, EUR J ENDOCRINOL, V146, P707, DOI 10.1530/eje.0.1460707
  6. Cavagnini F, 2001, ANN ENDOCRINOL-PARIS, V62, P168
  7. ETXABE J, 1994, CLIN ENDOCRINOL, V40, P479, DOI 10.1111/j.1365-2265.1994.tb02486.x
  8. Feelders RA, 2010, NEW ENGL J MED, V362, P1846, DOI 10.1056/NEJMc1000094
  9. Godbout A, 2010, EUR J ENDOCRINOL, V163, P709, DOI 10.1530/EJE-10-0382
  10. Henry RR, 2011, 13 EUR C END ROTT NE
  11. Hofland LJ, 2005, EUR J ENDOCRINOL, V152, P645, DOI 10.1530/eje.1.01876
  12. Hofland LJ, 2003, ENDOCR REV, V24, P28, DOI 10.1210/er.2000-0001
  13. Lila AR, 2010, ENDOCR PRACT, V16, P968, DOI 10.4158/EP10031.OR
  14. Lindholm J, 2001, J CLIN ENDOCR METAB, V86, P117, DOI 10.1210/jc.86.1.117
  15. National Cancer Institute, 2006, COMM TERM CRIT ADV E
  16. Newell-Price J, 2006, LANCET, V367, P1605, DOI 10.1016/S0140-6736(06)68699-6
  17. Pivonello R, 2009, J CLIN ENDOCR METAB, V94, P223, DOI 10.1210/jc.2008-1533
  18. van der Hoek J, 2005, AM J PHYSIOL-ENDOC M, V289, pE278, DOI 10.1152/ajpendo.00004.2005
  19. Vilar L, 2010, PITUITARY, V13, P123, DOI 10.1007/s11102-009-0209-8
  20. Webb SM, 2008, EUR J ENDOCRINOL, V158, P623, DOI 10.1530/EJE-07-0762

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC